The table below shows VERTEX PHARMACEUTICALS INC / MA's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$3.63B
-$492.60M
$3.54B
$4.13B
$2.64B
$3.25B
Capital expenditure
$437.60M
$297.70M
$200.40M
$204.70M
$235.00M
$259.80M
Investing cash flow
-$945.40M
-$3.77B
-$3.14B
-$321.10M
-$340.90M
$99.40M
Dividends paid
-
-
-
-
-
VRTX operating cash flow (10-K history)
VERTEX PHARMACEUTICALS INC / MA reported operating cash flow of $3.63B for fiscal year 2025. That is up 837.2% from -$492.60M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $236.10M (FY 2016) to $3.63B. Figures come from the company's audited annual reports as filed with the SEC.
